Clinical Trial Update: Thero2-01S22 in HER2-positive Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update for Thero2-01S22 in HER2-positive breast cancer (not yet recruiting).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Thero2-01S22

Snippet

Sponsor: Institut de cancérologie Strasbourg Europe | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING